drug
dose
critic
ill
patient
challeng
due
alter
drug
pharmacokineticspharmacodynam
associ
system
therapi
mani
drug
therapi
potenti
use
respiratori
system
altern
rout
drug
deliveri
aerosol
drug
deliveri
provid
mani
advantag
convent
therapi
given
respiratori
diseas
commonest
caus
critic
ill
use
aerosol
therapi
provid
high
local
drug
concentr
minim
system
side
effect
make
rout
attract
option
date
limit
evid
restrict
wider
applic
efficaci
aerosol
drug
therapi
depend
drugrel
factor
particl
size
molecular
weight
devic
factor
patientrel
factor
airway
anatomi
inhal
pattern
mechan
ventilationrel
factor
humidif
airway
review
identifi
relev
factor
requir
attent
optim
aerosol
drug
deliveri
achiev
better
drug
concentr
target
site
potenti
improv
clinic
outcom
main
goal
aerosol
achiev
high
drug
concentr
lung
tissu
aerosol
therapi
use
part
treatment
varieti
respiratori
diseas
inde
also
signific
interest
util
respiratori
system
portal
system
therapi
condit
pure
respiratori
natur
factor
larg
surfac
area
thin
airblood
barrier
vascular
epithelium
coupl
low
firstpass
metabol
enzymat
activ
could
achiev
high
bioavail
aerosol
drug
therapi
possibl
achiev
high
local
drug
concentr
therapeut
site
respiratori
patholog
rapid
onset
action
lower
system
side
effect
thu
led
renew
interest
field
aerosol
drug
therapi
intens
care
datura
administr
india
tobacco
ancient
south
america
smoke
pipe
north
american
indian
earli
use
airway
rout
system
drug
deliveri
vapor
opium
use
treatment
cough
anticholinerg
properti
inhal
herbal
prepar
use
treat
asthma
inhal
epinephrin
first
use
around
aerosol
therapi
use
mani
therapi
includ
bronchodil
corticosteroid
particular
interest
antibiot
administr
reemerg
recent
although
refer
use
inhal
penicillin
earli
first
random
control
trial
inhal
antibiot
first
report
cystic
fibrosi
cf
patient
critic
care
endotrach
antibiot
administr
first
report
klasterski
et
al
report
endotrach
polymyxin
effect
prevent
ventilatorassoci
pneumonia
tracheostom
patient
follow
studi
note
advers
effect
bronchospasm
poor
toler
well
concern
regard
emerg
drug
resist
associ
prolong
week
endotrach
administr
pharyng
aerosol
led
reduct
use
inhal
antibiot
even
investig
continu
prescrib
intratrach
antibiot
critic
ill
patient
often
success
especi
drugresist
pneumonia
antibiot
instil
practic
use
earli
studi
practic
larg
abandon
subsequ
use
bench
model
enabl
improv
understand
aerosol
factor
optim
ventil
paramet
devic
posit
circuit
effect
humid
enabl
optim
therapi
work
supplement
antibiot
studi
experiment
pneumonia
demonstr
higher
lung
tissu
concentr
antibiot
later
develop
new
gener
devic
ultrason
nebul
vibrat
mesh
nebul
vmn
encourag
studi
applic
aerosol
therapi
critic
care
abil
devic
consist
gener
desir
aerosol
particl
size
consid
optim
deep
lung
penetr
previous
formul
drug
use
aerosol
reconstitut
form
compound
develop
parenter
administr
poorli
toler
patient
due
hyperosmolar
ad
preserv
ie
phenol
induc
bronchial
irrit
bronchospasm
lead
abandon
rout
therapi
formul
issu
particularli
problemat
antibiot
aerosol
tobramycin
evalu
patient
cf
chronic
infect
increasingli
resist
pseudomona
aeruginosa
number
highqual
studi
use
preservativefre
isoosmolar
formul
tobramycin
show
improv
lung
function
decreas
exacerb
rate
reduct
sputum
bacteri
load
result
encourag
develop
applic
aerosol
antibiot
noncf
patient
popul
critic
care
critic
ill
patient
certain
anatomicophysiolog
chang
significantli
affect
pharmacokinet
pk
pharmacodynam
pd
characterist
thu
caus
dose
difficulti
mechan
ventil
patient
pose
challeng
effect
deliveri
aerosol
drug
variou
factor
need
consid
optim
achiev
desir
therapeut
outcom
aerosol
drug
therapi
research
interest
aerosol
drug
therapi
critic
ill
patient
yet
reflect
benchtobedsid
transfer
knowledg
one
report
mention
intensivist
routin
prescrib
aerosol
medic
report
also
highlight
lack
applic
scientif
principl
therapi
indic
need
educ
research
benchtobedsid
transfer
knowledg
anoth
studi
everi
fourth
critic
ill
patient
everi
fifth
ventil
patient
receiv
aerosol
therapi
recent
intern
survey
perform
europ
asia
australasia
north
america
show
although
icu
practic
antibiot
nebul
actual
follow
recommend
given
common
use
aerosol
critic
care
yet
uncertainti
optim
approach
administr
articl
aim
discuss
essenti
concept
relat
aerosol
drug
therapi
critic
care
aerosol
defin
suspens
liquid
solid
gaseou
medium
success
aerosol
consider
aerosol
system
requir
aerosol
system
includ
drug
aerosol
devic
diseas
ie
target
site
patient
respiratori
system
ventil
addit
factor
mechan
ventil
patient
aim
aerosol
system
produc
aerosol
characterist
suitabl
drug
deliveri
lung
drug
deposit
absorpt
metabol
elimin
essenti
determin
pharmacokinet
profil
result
aerosol
system
key
express
use
evalu
aerosol
system
perform
includ
follow
emit
dose
ed
amount
drug
exit
deliveri
devic
fine
particl
fraction
fpf
mass
particl
cutoff
diamet
overal
effici
aerosol
system
composit
ed
dose
deliv
lung
fpf
surrog
marker
lung
bioavail
ed
fpf
normal
determin
vitro
govern
particul
properti
devic
design
bioavail
drug
influenc
patient
factor
airway
lung
anatomi
drug
permeabl
across
membran
metabol
drug
phagocyt
clearanc
lung
well
fpf
efficaci
aerosol
drug
depend
dose
deposit
target
site
action
well
distribut
lung
deposit
airway
occur
inerti
impact
gravit
sediment
diffus
brownian
motion
fig
turbul
high
air
veloc
associ
aerosol
inerti
impact
method
predomin
first
branch
airway
proxim
region
target
aerosol
therapi
diseas
copd
asthma
ventilatorassoci
tracheobronch
distal
five
six
airway
gener
howev
sediment
predomin
due
lower
air
veloc
alveolar
level
minim
air
veloc
mean
effect
impact
occur
combin
sediment
diffus
influenc
drug
deposit
aerosol
particl
therapeut
purpos
rang
diffus
predomin
mechan
lung
deposit
optim
techniqu
aerosol
import
achiev
distal
airway
alveolar
deposit
factor
affect
aerosol
drug
deliveri
critic
ill
patient
drug
concentr
lung
tissu
affect
aerosol
dose
administ
patient
factor
devic
factor
formul
drug
mechan
ventil
mv
introduc
addit
element
circuit
ventil
associ
factor
purpos
describ
factor
affect
aerosol
therapi
critic
ill
patient
could
classifi
two
group
ventil
patient
nonventil
patient
figur
show
factor
conduc
effect
aerosol
drug
deliveri
critic
ill
mechan
ventil
nonmechan
ventil
patient
group
airflow
tidal
volum
influenc
effect
airway
anatomi
aerosol
deposit
patient
suffer
airway
obstruct
asthma
copd
impair
mucociliari
clearanc
mucou
retent
drug
poor
transmuc
permeabl
eg
aerosol
aminoglycosid
could
mean
reduc
drug
deliveri
henc
impair
efficaci
although
yet
confirm
clinic
studi
chronic
inflamm
may
result
airway
remodel
chang
dynam
airflow
impair
mucociliari
clearanc
thu
reduc
pulmonari
drug
deposit
chang
lead
proxim
shift
airway
deposit
pattern
aerosol
significanceabnorm
airway
impair
mucociliari
clearanc
serv
barrier
effect
aerosol
drug
therapi
target
site
lung
parenchyma
airflow
homogen
throughout
lung
even
health
result
upright
patient
apic
portion
lung
receiv
lung
deposit
order
higher
ratio
compar
basal
region
differ
significantli
reduc
supin
posit
moreov
lung
diseas
region
add
heterogen
region
airflow
import
determin
aerosol
deposit
exampl
shown
lower
deposit
area
poor
air
flow
ie
atelectat
lung
area
antibiot
larg
bodi
work
experiment
pneumonia
model
demonstr
lung
tissu
concentr
nebul
amikacin
use
ultrason
nebul
significantli
higher
concentr
result
administr
via
intraven
rout
inde
even
though
deposit
nebul
drug
decreas
sever
pneumonia
still
result
higher
lung
tissu
concentr
achiev
intraven
administr
figur
illustr
phenomenon
group
also
demonstr
nebul
amikacin
result
greater
bactericid
activ
lead
greater
steril
rate
compar
intraven
rout
compar
continu
intraven
niv
noninvas
ventil
hme
heat
moistur
exchang
pmdi
pressur
meter
dose
inhal
aad
adapt
aerosol
devic
vmn
vibrat
mesh
nebul
dpi
dri
powder
inhal
peep
posit
endexpiratori
pressur
fig
effect
region
lung
aerat
pneumonia
drug
concentr
lung
relationship
lung
aerat
pulmonari
concentr
amikacin
differ
rout
administr
b
relationship
rout
drug
administr
pulmonari
concentr
amikacin
differ
sever
pneumonia
pulmonari
concentr
deriv
homogen
lung
tissu
specimen
measur
immunoenzymat
method
figur
deriv
elman
et
al
infus
ceftazidim
frequent
nebul
achiev
higher
lung
tissu
concentr
better
bactericid
effect
experiment
model
pseudomona
pneumonia
significancediffer
region
lung
aerat
may
explain
variabl
therapeut
outcom
amongst
differ
lung
diseas
critic
ill
spontan
breath
patient
air
flow
like
turbul
lead
impact
proxim
airway
drug
depend
lung
deposit
effect
result
decreas
pharmacolog
effect
contrast
laminar
flow
pattern
consid
enabl
optim
lung
deposit
critic
ill
patient
certain
mv
set
eg
squar
wave
airflow
pattern
enabl
gener
laminar
airflow
improv
drug
deposit
lung
hand
lower
flow
may
reduc
ed
dri
powder
inhal
dpi
use
use
pressur
meter
dose
inhal
pmdi
valv
hold
chamber
vhc
spacer
could
mitig
effect
significancewhilst
laminar
flow
pattern
would
benefici
aerosol
drug
deliveri
mechanist
data
need
confirm
use
clinic
trial
diseas
pneumonia
inflammatori
lung
diseas
result
defici
lung
surfact
content
andor
effect
drug
high
solubl
probabl
uniform
dispers
compar
insolubl
drug
inferenti
solubl
drug
like
longer
effect
lung
resid
time
thu
improv
drug
potenc
surfact
defici
associ
atelectasi
turn
impair
drug
deposit
studi
surfact
replac
therapi
acut
lung
injuri
ard
howev
fail
demonstr
benefit
may
even
deem
harm
aerosol
surfact
therapi
studi
mucokinet
agent
specif
condit
applic
purpos
critic
ill
patient
need
studi
significanceuncertain
benefit
requir
studi
demonstr
effect
surfact
major
fraction
aerosol
drug
entrap
mucou
conduct
airway
factor
particl
size
solubl
lipophil
charg
govern
abil
drug
penetr
mucou
barrier
exampl
steroid
antimicrobi
agent
seen
reduc
transmuc
transport
atelectasi
common
occurr
major
critic
ill
patient
may
advers
effect
drug
deposit
may
result
heterogen
distribut
lung
significanceboth
mucou
atelectasi
serv
barrier
effect
aerosol
drug
therapi
detail
discuss
effect
devicerel
factor
review
elsewher
appropri
particl
size
import
enabl
adequ
concentr
target
site
particl
size
also
determin
mechan
deposit
respiratori
system
particl
distribut
deep
smaller
airway
report
deposit
effici
smaller
particl
consid
optim
droplet
size
effici
deposit
alveolar
airspac
system
deliveri
regard
effici
aerosol
devic
defin
abil
gener
aerosol
desir
particl
size
rang
pmdi
spacer
vhc
demonstr
superior
deposit
efficaci
nebul
variou
studi
although
vhc
use
mechan
ventil
due
inabl
trigger
activ
devic
dpi
propel
inher
breathsynchronizedactiv
produc
littl
variat
particl
size
featur
may
make
dpi
prefer
deliveri
devic
critic
ill
patient
howev
poor
respiratori
reserv
diminish
patient
effort
barrier
achiev
desir
respiratori
pattern
effect
use
dpi
dpi
also
vari
wide
efficaci
use
mechan
ventil
patient
typic
possibl
standard
set
thu
dpi
present
use
stabl
unventil
patient
group
pmdi
dpi
limit
formul
avail
deliv
devic
nebul
differ
devic
use
transform
liquid
formul
suspens
aerosol
form
devic
use
deliv
larger
volum
drug
aerosol
either
intermitt
continu
prophylaxi
treatment
purpos
depend
mechan
oper
three
type
nebul
jet
ultrason
smn
jet
nebul
cheapest
simplest
albeit
ineffici
drug
deliveri
drawback
nois
poor
dose
control
requir
chang
ventil
set
airflow
tidal
volum
although
improv
made
form
reservoir
new
baffl
ensur
optim
particl
size
breathenhanc
version
jet
nebul
could
increas
fpf
improv
drug
deliveri
reduc
drug
loss
limit
studi
evalu
effici
newer
jet
nebul
data
certainli
lack
critic
care
set
newer
ventil
inbuilt
nebul
system
improv
effici
synchron
nebul
respiratori
cycl
ultrason
nebul
infrequ
use
also
limit
expens
larg
size
increas
concentr
drug
nebul
caus
thermal
inactiv
nebul
drug
mesh
nebul
result
improv
nebul
technolog
although
effici
signific
advantag
dearth
human
studi
use
mesh
nebul
despit
major
improv
technolog
need
reduc
cost
devic
tabl
compar
contrast
principl
advantag
disadvantag
differ
nebul
significancewher
possibl
pmdi
spacer
use
dpi
use
like
limit
critic
care
nebul
devic
select
accord
formul
use
desir
site
deposit
effect
rate
extent
absorpt
aerosol
substanc
depend
molecular
weight
ph
electr
charg
solubl
stabil
macromolecul
kda
observ
better
absorb
minut
bloodstream
follow
inhal
airway
eg
insulin
molecular
weight
mw
kda
howev
macromolecul
kda
absorb
slowli
hour
eg
albumin
mw
kda
molecul
mw
kda
may
need
absorpt
enhanc
absorpt
alveoli
significancedepend
desir
site
action
appropri
drug
formul
use
alongsid
deliveri
devic
would
gener
suitabl
particl
size
combin
helium
oxygen
heliox
reduc
ga
densiti
increas
aerosol
deposit
particularli
peripher
lung
pmdi
heliox
report
increas
aerosol
drug
deliveri
mv
howev
jet
nebul
heliox
also
increas
nebul
time
requir
higher
ga
flow
compens
lowdens
ga
experiment
studi
increas
lung
deposit
nebul
ceftazidim
bronchopneumon
lung
compar
healthi
lung
significancefurth
investig
largescal
trial
need
evalu
effect
heliox
critic
ill
varieti
propos
mechan
patient
sputum
thought
caus
aminoglycosid
inactiv
result
sputum
antagon
significanceuncertain
therefor
effect
sputum
antagon
requir
invivo
investig
current
data
cf
patient
support
use
inhal
aminoglycosid
aerosol
therapi
routin
use
mechan
ventil
patient
invas
noninvas
inher
challeng
due
interplay
varieti
factor
howev
nebul
techniqu
compar
patient
posit
formul
temperatur
endotrach
tube
size
presenc
airway
obstruct
ventilatori
asynchroni
flow
pattern
respiratori
rate
dose
frequenc
appli
posit
nebul
circuit
import
factor
influenc
deliveri
lung
higher
turbul
lower
drug
deposit
distal
airway
optim
set
nebul
toler
mani
patient
sever
hypoxemia
associ
ard
pneumonia
requir
addit
deep
sedat
relax
prolong
durat
mv
disposit
unilater
pneumonia
might
imbalanc
current
nebul
pmdi
without
spacer
two
type
devic
avail
use
mechan
ventil
patient
depend
site
action
devic
produc
appropri
particl
size
use
nebul
take
consider
longer
time
deliv
standard
dose
compar
devic
also
variat
effici
nebul
type
nebul
differ
batch
effect
accentu
coupl
effect
differ
ventil
mode
lung
mechan
inadequ
clean
disinfect
nebul
increas
risk
nosocomi
pneumonia
compar
jet
nebul
vmn
could
increas
drug
deliveri
although
discuss
previous
nebul
choic
depend
formul
desir
deliveri
site
pmdi
easi
administ
requir
less
staff
time
provid
reliabl
dose
minim
risk
bacteri
contamin
compar
nebul
use
collaps
spacer
circuit
circuit
need
disconnect
pmdi
also
costeffect
nebul
although
bronchodil
antiinflammatori
agent
avail
devic
seen
use
pmdi
significantli
reduc
overal
cost
care
could
equal
effect
treatment
inflammatori
airway
diseas
asthma
copd
invitro
studi
shown
improv
aerosol
deliveri
larg
spacer
compar
small
spacer
pmdi
vmn
publish
recommend
correct
method
use
avail
other
shown
modest
improv
aerosol
deliveri
significancepmdi
possibl
effect
nebul
vmn
appear
superior
nebul
type
although
choic
depend
drug
formul
properti
desir
deposit
site
time
insuffici
evid
support
use
either
deliveri
method
use
spacer
pmdi
need
clinic
trial
test
efficaci
invitro
studi
use
adult
ventil
shown
use
vibrat
mesh
ultrason
nebul
well
pmdi
posit
cm
ypiec
inspiratori
limb
circuit
yield
highest
drug
deliveri
constant
flow
pattern
ventil
vmn
connect
endotrach
tube
could
effect
howev
jet
nebul
seem
perform
better
posit
closer
ventil
possibl
due
effect
continu
ga
flow
charg
circuit
function
aerosol
reservoir
noninvas
ventil
niv
use
vmn
posit
exhal
port
effici
drug
deliveri
compar
exhal
port
significanceth
best
posit
aerosol
gener
may
cm
ypiec
inspiratori
limb
invivo
studi
requir
make
definit
conclus
although
endotrach
tube
tracheostomi
tube
present
certain
similar
tracheostomi
tube
shorter
curv
endotrach
tube
patient
mechan
ventil
tpiec
interfac
tracheostomi
tube
nebul
demonstr
effect
tracheostomi
mask
prefer
inner
cannula
remov
nebul
particularli
smaller
size
tube
smaller
diamet
airway
lead
increas
resist
airflow
result
increas
drug
deposit
artifici
airway
tracheobronchi
region
significancefor
aerosol
drug
deliveri
larger
size
artifici
airway
better
mechan
ventil
patient
temperatur
averag
rel
humid
requir
prevent
heat
loss
humidif
also
prevent
dri
secret
mucou
plug
consequ
atelectasi
two
major
method
humidificationact
passiv
activ
method
includ
heat
humidifi
hh
passiv
method
includ
heat
moistur
exchang
hme
humidif
thought
signific
effect
aerosol
drug
deliveri
hygroscop
effect
humidif
may
growth
particl
size
pass
airway
increas
size
may
reduc
peripher
lung
drug
deposit
henc
pharmacolog
efficaci
compar
humidifi
condit
drug
deliveri
doubl
nonhumidifi
condit
recommend
hh
ceas
durat
therapi
interest
invitro
nonmechan
ventil
model
use
excipi
enhanc
growth
eeg
submicrometr
particl
one
group
demonstr
increas
aerosol
deposit
airway
lung
investig
method
requir
har
effect
mv
hme
physic
barrier
place
deliveri
devic
patient
particul
air
filter
expiratori
limb
use
protect
ventil
flow
meter
could
get
satur
result
airflow
obstruct
recommend
filter
chang
everi
nebul
treatment
significanceus
hme
particul
air
filter
nebul
could
result
air
flow
obstruct
awar
routin
chang
air
filter
nebul
perform
ventil
breath
characterist
import
effect
efficaci
aerosol
deliveri
slower
inspiratori
flow
long
inspiratori
time
tidal
volum
ml
use
pmdi
correl
well
improv
aerosol
deliveri
higher
bia
flow
seen
reduc
deliveri
efficaci
nebul
deceler
flow
pattern
consid
inferior
constant
flow
pattern
drug
deliveri
effect
ventil
mode
neglig
pmdi
deliveri
effici
patient
niv
seen
compar
less
howev
must
rememb
specif
techniqu
ventil
may
produc
greater
benefit
rel
detriment
drug
deliveri
eg
niv
asthma
henc
acut
asthma
niv
plu
nebul
effect
nebul
alon
prescrib
ventilatori
pattern
may
practic
critic
ill
patient
effect
combin
tidal
volum
flow
ventil
paramet
aerosol
deliveri
calibr
drug
deliveri
devic
use
invitro
model
significancetid
volum
ml
may
enhanc
aerosol
drug
deliveri
niv
result
effect
therapi
despit
reduc
drug
deliveri
condit
like
asthma
ventil
set
optim
nebul
howev
could
lead
patientventil
dyssynchroni
sever
hypoxem
patient
eg
due
sever
pneumonia
thu
requir
deep
sedat
may
increas
durat
mv
posit
endexpiratori
pressur
peep
commonli
use
ventil
set
part
lung
protect
ventilatori
strategi
sever
lung
diseas
peep
signific
effect
region
ventil
perfus
henc
could
influenc
pk
aerosol
drug
anim
model
use
radiotrac
peep
found
enhanc
aerosol
clearanc
could
due
stretch
alveolar
epithelium
enhanc
distribut
aerosol
bloodstream
significancepeep
potenti
benefici
although
data
need
quantifi
effect
aerosol
drug
deliveri
choic
one
antimicrobi
anoth
consid
efficaci
data
cost
local
antimicrobi
resist
pattern
drug
avail
aminoglycosid
requir
tissu
concentr
higher
mic
maxim
effect
airway
inflamm
could
increas
system
absorpt
molecular
weight
low
serum
aminoglycosid
concentr
monitor
avoid
system
toxic
betalactam
rapidli
clear
airway
requir
frequent
administr
colistin
administ
anion
methanesulfon
formcolistimeth
despit
high
dose
million
unit
colistimeth
everi
hour
mg
colistimeth
equival
mg
colistin
base
administ
colon
patient
bronchiectasi
lung
epitheli
line
fluid
concentr
mgl
hour
upper
threshold
eucast
mic
breakpoint
pseudomona
even
mgl
hour
mani
patient
eucast
mic
breakpoint
klebsiella
sp
acinetobact
baumannii
therefor
high
dose
million
unit
everi
hour
consid
pneumonia
despit
deliveri
drug
via
inhal
rout
signific
extrapulmonari
drug
loss
may
mean
actual
amount
drug
deliv
might
less
ed
trachea
even
less
reach
alveolar
space
factor
taken
account
calcul
dose
regimen
number
anim
studi
use
better
understand
mechanist
principl
aerosol
therapi
guillon
et
al
show
effect
teicoplanin
nebul
mv
good
pk
properti
compar
intraven
rout
other
success
nebul
ceftazidim
achiev
high
local
concentr
studi
requir
quantifi
exact
dose
amount
schedul
use
pk
studi
dose
differ
patient
colon
tracheobronch
pneumonia
increas
dose
eg
million
unit
colistin
requir
longer
period
nebul
hour
well
toler
patient
suffer
ard
significanceth
inhal
drug
dose
like
significantli
higher
expect
due
concern
drug
loss
pkpd
studi
requir
guid
inhal
drug
dose
drug
loss
occur
exhal
phase
ventil
minim
loss
actuat
inhal
nebul
could
match
inspir
howev
use
spacerpmdi
combin
negat
effect
lack
breath
synchron
effect
breath
synchron
aerosol
deposit
unproven
use
radiolabel
aerosol
dubu
et
al
show
signific
increas
aerosol
deposit
neonat
ventil
breath
synchron
investig
thu
need
evalu
effect
breath
synchron
aerosol
deposit
event
devic
introduc
synchron
drug
deliveri
facilit
toler
significancebreath
actuat
drug
deliveri
devic
potenti
improv
drug
deliveri
howev
trialbas
data
requir
establish
efficaci
aerosol
drug
deposit
highflow
nasal
oxygen
therapi
becom
wide
preval
therapi
intens
care
number
factor
influenc
nebul
therapi
patient
use
high
flow
studi
recent
invitro
model
posit
nebulizera
posit
distant
humidifi
closer
patient
improv
deliveri
drug
upstream
nebul
typevmn
demonstr
improv
deliveri
compar
jet
nebul
although
nebul
choic
depend
formul
desir
site
action
airflowth
deliveri
respir
mass
lower
higher
airflow
improv
lower
airflow
patient
effortsconvers
effect
airflow
highflow
oxygen
system
situat
mimick
respiratori
distress
ie
increas
patient
inspiratori
airflow
deliveri
fact
better
open
mouth
contrari
signific
differ
close
mouth
respect
drug
deliveri
significancelimit
data
suggest
better
drug
deliveri
use
vmn
lower
airflow
even
patient
respiratori
distress
invivo
studi
need
perform
use
highflow
oxygen
therapi
devic
contemporari
applic
aerosol
therapi
critic
care
focu
antibiot
tabl
summar
common
applic
aerosol
therapi
critic
care
aerosol
bronchodil
corticosteroid
effect
util
critic
care
aerosol
antibiot
quickli
gain
data
support
posit
critic
care
armamentarium
improv
drug
formul
deliveri
devic
known
optim
condit
requir
effect
aerosol
therapi
summar
fig
despit
develop
concern
best
evid
administr
appli
particularli
aerosol
antibiot
therapi
clinic
experiment
studi
data
aminoglycosid
colistin
perhap
numer
antibiot
critic
care
aminoglycosid
concentrationdepend
antibiot
wherebi
bactericid
effect
best
describ
c
max
mic
ratio
studi
shown
intraven
aminoglycosid
penetr
poorli
epitheli
line
fluid
escherichia
coli
inocul
pneumonia
model
aerosol
amikacin
seen
achiev
signific
lung
concentr
figur
illustr
phenomenon
hand
repeat
administr
accumul
effect
henc
toxic
concern
aerosol
amikacin
experiment
studi
serum
concentr
amikacin
higher
aerosol
amikacin
use
pneumonia
model
compar
healthi
lung
moreov
combin
intraven
aerosol
aminoglycosid
shown
increas
cure
rate
compar
aerosol
antibiot
alon
thu
treatment
ventilatorassoci
pneumonia
aerosol
therapi
alon
may
adequ
without
need
intraven
therapi
decreas
risk
system
toxic
colistin
also
concentrationdepend
antibiot
anoth
antibiot
use
wide
aerosol
form
colistin
aerosol
approv
fda
licens
human
use
china
like
aminoglycosid
colistin
poor
lung
penetr
given
intraven
experiment
studi
shown
rapid
high
bactericid
effect
achiev
aerosol
colistin
figur
illustr
phenomenon
demonstr
lu
et
al
low
serum
concentr
result
aerosol
colistin
inocul
pneumonia
model
risk
toxic
minim
prospect
observ
studi
lu
et
al
demonstr
similar
clinic
cure
patient
vap
suscept
p
aeruginosa
baumannii
treat
intraven
colistin
mdr
strain
treat
nebul
colistin
combin
intraven
aminoglycosid
aerosol
colistin
shown
superior
aerosol
colistin
alon
although
implement
worldwid
benefit
use
aerosol
colistin
instead
system
colistin
avoid
nephrotox
confirm
one
random
clinic
trial
observ
cohort
studi
report
less
advers
event
random
clinic
trial
inde
potenti
caus
system
toxic
eg
nephrotox
aminoglycosid
local
toxic
form
airway
irrit
cough
often
bronchospasm
worsen
hypoxemia
secondari
arrhythmia
well
pulmonari
injuri
use
aerosol
therapi
ventil
malfunct
obstruct
expiratori
filter
report
contraind
use
drug
lipid
compon
lactos
sugar
formul
zanamivir
lipidbas
amphotericin
formul
care
monitor
potenti
increas
airway
pressur
oxygen
satur
requir
anticip
sever
advers
event
modif
ventil
paramet
appropri
jet
nebul
use
tabl
toler
patient
increas
work
breath
ventil
dyssynchroni
requir
addit
sedat
poor
toler
may
preclud
use
aerosol
antibiot
patient
pao
fio
mmhg
high
peep
requir
initi
concern
regard
drug
resist
result
intratrach
nebul
use
antibiot
polymyxin
b
investig
appear
support
aerosol
antibiot
use
newer
devic
like
intraven
therapi
confer
bacteri
resist
probabl
link
previousgener
nebul
techniqu
administr
instil
pharyng
aerosol
etc
howev
find
must
interpret
reservedli
longterm
followup
perform
toler
aerosol
differ
drug
nebul
differ
durat
time
consequ
might
limit
use
aerosol
patient
ard
sever
hypoxemia
sever
pneumonia
contrast
ventilatorassoci
tracheobronch
often
poor
toler
high
dose
colistin
nebul
infus
volum
may
repres
hour
nebul
mani
patient
requir
ad
sed
relax
potenti
increas
risk
myopathi
hypotens
requir
would
associ
prolong
mv
period
extra
length
stay
clinic
trial
therefor
use
predefin
outcom
paramet
rather
surrog
control
hypoxemia
care
record
advers
event
environment
contamin
result
aerosol
drug
open
circuit
system
pose
small
signific
risk
caregiv
use
expiratori
filter
valv
aerosol
deliveri
devic
could
minim
occup
risk
exposur
assess
intervent
mitig
risk
implement
use
aerosol
antibiot
recommend
chang
filter
everi
therapi
optim
aforement
factor
could
lead
effect
drug
deliveri
howev
import
realiz
aerosol
medic
automat
lead
benefici
drug
effect
may
fact
harm
shown
studi
aerosol
therapi
provid
effect
drug
deliveri
critic
ill
patient
care
consider
variou
element
affect
pharmacolog
effect
aerosol
therapi
essenti
deriv
optim
therapeut
benefit
effect
drug
deliveri
alon
ensur
success
aerosol
drug
therapi
crucial
drug
aerosol
form
efficaci
specif
diseas
condit
deriv
clinic
benefit
good
qualiti
data
clinic
experi
support
use
bronchodil
salbutamol
antiinfect
tobramycin
aztreonam
colistin
antiinflammatori
agent
budesonid
although
applic
principl
possibl
provid
aerosol
drug
deliveri
effect
therapi
diseas
condit
yet
proven
scarciti
highqual
trialbas
data
area
quantifi
effect
agent
critic
ill
patient
given
challeng
effect
treatment
critic
ill
patient
necessari
optim
mani
factor
possibl
effect
drug
deliveri
henc
import
guidelin
aerosol
therapi
develop
envisag
technolog
becom
matur
rigor
evalu
divers
rang
aerosol
therapi
uniqu
advantag
ie
control
releasesustain
releas
direct
target
specif
indic
may
possibl
tabl
optim
ventil
paramet
requir
aerosol
antibiot
modifi
lu
et
al
nebul
placementin
inspiratori
limb
cm
proxim
ypiec
expir
aerosol
particl
collect
filter
hme
heat
moistur
exchang
rr
respiratori
rate
e
inspiratori
expiratori
ratio
vt
tidal
volum
fig
comparison
lung
concentr
measur
hplc
bacteri
burden
colistin
aerosol
intraven
administr
sampl
taken
hour
third
aerosol
aerosol
group
fourth
infus
intraven
group
hour
bacteri
inocul
diagram
deriv
data
lu
et
al
